Antibodies labelled with radioisotopes or the sequential administrationof an antibody and a radioactive secondary agent facilitate theย in vivo detection and/or characterisation of cancers by positron emission tomography (PET) or by single-photon emission computed tomography (SPECT) imaging.
There are drawbacks to both methods, including prolonged exposure to radiation and ย ensuring that both the antibody and the radiolabelled secondary agent areย suitably designed so that they bind rapidly upon contact at the tumor.
A recent publication (1) investigated a alternative method utilizing the HaloTagยฎ dehalogenase enzymeย HaloTagยฎ is a dehalogenase enzyme (33 kDa) thatย contains an engineered cavity designed to accommodate the reactive chloroalkane group of a HaloTagยฎ ligand (HTL). Upon entering theย enzyme cavity, the terminal chlorine atom rapidly undergoes nucleophilic displacement, and a covalent adduct is formed, effectively anchoring the HaloTagยฎ ligand in a precise location.
Three new HaloTagยฎ ligands were synthesized and each labelled with the SPECT radionuclide indium-111ย 111In-HTL-1ย and the dual-modality HaloTagยฎ ligands,111In-HTL-2 and111;In-HTL-3 containing TMR which allows complementary imaging data).
For the validation ofย the pretargeting strategy based on these HaloTagยฎ ligands, the target human epidermal growth factor receptor 2 (HER2)was selected. Trastuzumab (Herceptinยฎ) was selected as the primary targeting agent and was modified with HaloTagยฎ protein via the trans-cyclooctene/tetrazine ligation.
All three 111In-labelled HaloTaยฎg ligands exhibited significantly higher binding to the HER2 expressing when compared to negative controls.
Literature Cited
Knight, J. C et al.(2015) Development of an enzymatic pretargeting strategy for dual-modality imaging.ย Chem. Commun. 51, 4055โ8.


